Home> Products> long lasting blood sugar control

{ "products": [ { "_id": "68d51d9a26579f4bc195771a", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Glimepiride IP1 mg, Voglibose IP 0.2 MG & Metformin Hydrochloride IP 500 mg ", "description": "GLIMITERIS MV1 0.2 is an advanced fixed-dose combination (FDC) medication designed for adults with Type 2 Diabetes Mellitus (T2DM) who require more than lifestyle modifications or single/dual therapy to maintain optimal blood sugar levels. This innovative formulation brings together the power of three well-established antidiabetic agents—Glimepiride (1 mg), Voglibose (0.2 mg), and Metformin Hydrochloride SR (500 mg)—to provide comprehensive glycemic control.\n\nIt is particularly effective for patients struggling with postprandial hyperglycemia, fasting glucose regulation, and HbA1c reduction, making it a preferred choice in cases of poorly controlled diabetes.\n\n \n\nMechanism of Action\nThe therapeutic benefit of GLIMITERIS MV1 0.2 comes from the unique synergy of its three components, each targeting different aspects of glucose metabolism:\n\n1. Glimepiride (1 mg) – Sulfonylurea\nStimulates insulin secretion by activating pancreatic beta cells.\n\nProvides a long-lasting effect with comparatively lower hypoglycemia risk than older sulfonylureas.\n\nHelps reduce both fasting and postprandial glucose levels.\n\n2. Voglibose (0.2 mg) – Alpha-Glucosidase Inhibitor\nDelays the breakdown and absorption of carbohydrates in the intestine.\n\nMinimizes post-meal glucose spikes (PPBG).\n\nActs locally in the gut and has minimal systemic absorption, which reduces systemic side effects.\n\n3. Metformin Hydrochloride SR (500 mg) – Biguanide\nDecreases hepatic glucose production (gluconeogenesis).\n\nImproves peripheral insulin sensitivity, enhancing glucose uptake in muscles.\n\nDoes not cause hypoglycemia on its own.\n\nThe sustained-release (SR) formulation ensures extended control and reduces gastrointestinal side effects.\n\n \n\nIndications\nGLIMITERIS MV1 0.2 is indicated for:\n\nAdults with Type 2 Diabetes Mellitus.\n\nPatients inadequately controlled with monotherapy or dual therapy.\n\nManagement of fasting and postprandial hyperglycemia.\n\nLong-term HbA1c reduction as part of a comprehensive diabetes care plan.\n\n \n\nKey Benefits\n✅ Comprehensive Blood Sugar Control – Acts on fasting, post-meal, and long-term HbA1c levels.\n✅ Postprandial Spike Management – Voglibose effectively controls carbohydrate-induced sugar surges.\n✅ Reduced Pill Burden – Combines three medicines into a single tablet.\n✅ Lower Hypoglycemia Risk – Metformin and Voglibose balance out Glimepiride’s insulin-secreting effect.\n✅ Weight Management Support – Metformin may promote modest weight loss or prevent weight gain.\n✅ Improved Tolerability – SR formulation of Metformin enhances gastrointestinal comfort.\n\n \n\nDosage and Administration\nRecommended dose: One tablet once or twice daily with meals, or as directed by the physician.\n\nAdministration tips:\n\nTake with the first bite of a main meal to maximize Voglibose’s effect.\n\nSwallow whole with water; do not crush or chew the SR tablet.\n\nDose adjustments: Based on blood sugar monitoring, clinical response, and renal/hepatic function.\n\n \n\nContraindications\nGLIMITERIS MV1 0.2 is not suitable for patients with:\n\nType 1 diabetes or diabetic ketoacidosis.\n\nSevere renal impairment (eGFR <30 mL/min/1.73 m²).\n\nHepatic dysfunction.\n\nSevere gastrointestinal diseases.\n\nHistory of lactic acidosis.\n\nHypersensitivity to Glimepiride, Voglibose, or Metformin.\n\nPregnancy and lactation (unless strictly advised by a physician).\n\n \n\nWarnings and Precautions\nHypoglycemia: Risk is higher when combined with other antidiabetics or with missed meals.\n\nLactic Acidosis: A rare but life-threatening effect of Metformin—renal function monitoring is essential.\n\nGI Side Effects: Voglibose and Metformin may cause bloating, flatulence, or diarrhea (usually temporary).\n\nVitamin B12 Monitoring: Long-term Metformin use may reduce B12 absorption.\n\nLiver and Kidney Function: Regular monitoring is recommended for safe long-term use.\n\n \n\nAdverse Effects\nCommon:\nGlimepiride: Mild hypoglycemia, dizziness, slight weight gain.\n\nVoglibose: Gas, abdominal discomfort, mild diarrhea.\n\nMetformin SR: Nausea, bloating, metallic taste, loose stools.\n\nRare but Serious:\nLactic acidosis (from Metformin).\n\nSevere hypoglycemia (especially if meals are skipped).\n\nAllergic reactions such as rash, itching, or swelling.\n\nElevated liver enzymes.\n\nSeek medical attention if symptoms such as rapid breathing, confusion, severe fatigue, or muscle pain occur.\n\n \n\nDrug Interactions\nIncreased hypoglycemia risk: With insulin, beta-blockers, and sulfonylureas.\n\nReduced Metformin efficacy: With corticosteroids, estrogens, and diuretics.\n\nLactic acidosis risk: Higher with alcohol or iodinated contrast agents. ", "price": 263.0, "discountamount": 80.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2182, "imageuri": "https://productimages.withfloats.com/actual/68d51d9cdf1a4ca2c252370a.png", "tileimageuri": "https://productimages.withfloats.com/tile/68d51d9cdf1a4ca2c252370a.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-09-25T10:46:50.098Z", "updatedon": "2025-10-02T11:20:20.402Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/glimepiride-ip1-mg-voglibose-ip-0-2-mg-metformin-hydrochloride-ip-500-mg-/2182", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "GLIMITERIS MV1 0.2", "category": "", "tags": [], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "6842b74dc10e9000933fa1d7", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "TRELAQWK 50", "description": "TRELAQWK 50 is a modern, once-a-week oral antidiabetic medication containing Trelagliptin 50mg, developed to support adults with type 2 diabetes mellitus (T2DM). This formulation is designed to improve blood glucose regulation while offering patients the convenience of weekly dosing. Created under rigorous quality standards, TRELAQWK 50 combines therapeutic effectiveness with enhanced compliance and lifestyle ease.\n\nActive Ingredient:\nTrelagliptin 50mg\nA next-generation DPP-4 (Dipeptidyl Peptidase-4) inhibitor with an extended half-life, enabling once-weekly administration. It helps improve glycemic control by preserving incretin hormones that naturally support insulin secretion and reduce glucagon production.\n\nKey Advantages:\nDelivers long-lasting blood sugar control with just one tablet per week\n\nEnhances insulin production and decreases glucagon levels in a glucose-dependent manner\n\nEffectively lowers both fasting and post-meal blood sugar levels\n\nPerfect for patients who find daily medications challenging\n\nLowers the risk of hypoglycemia when not combined with insulin or sulfonylureas\n\nContributes to better HbA1c levels over continued use\n\nMechanism of Action:\nTRELAQWK 50 functions by inhibiting the DPP-4 enzyme, which degrades incretin hormones like GLP-1 (Glucagon-Like Peptide-1) and GIP (Glucose-Dependent Insulinotropic Polypeptide). By preventing their breakdown, Trelagliptin extends the action of these hormones, resulting in increased insulin release and reduced glucagon levels. This mechanism is particularly effective after meals, helping maintain optimal blood glucose levels throughout the week.\n\nUsage Instructions:\nTake one tablet weekly, ideally on the same day each week\n\nCan be taken with or without meals\n\nSwallow whole with water—do not crush or chew\n\nFollow your doctor's dosing guidelines exactly\n\nIf you miss a dose, do not take two tablets together; speak with your doctor for guidance\n\nPossible Side Effects:\nTRELAQWK 50 is usually well-tolerated. However, some individuals may notice:\n\nHeadache\n\nCommon cold-like symptoms (nasopharyngitis)\n\nMild diarrhea\n\nGastrointestinal discomfort\n\nRare allergic responses like skin rashes or itching\n\nShould any side effects persist or worsen, consult your healthcare provider immediately.", "price": 375.0, "discountamount": 112.5, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": [ "offering patients", "worsen consult", "skin rashes", "chew follow", "meals swallow", "dpp4 enzyme", "sulfonylureas contributes", "enhanced compliance", "support adults", "trelaqwk 50trelaqwk 50", "hormones resulting", "hba1c levels", "tablet weekly ideally", "week usage instructions", "increased insulin release", "reduced glucagon levels", "degrades incretin hormones", "decreases glucagon levels", "preserving incretin hormones", "healthcare provider immediately", "side effects persist", "doctors dosing guidelines", "breakdown trelagliptin extends", "glp1 glucagonlike peptide1", "weekly dosing created" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2131, "imageuri": "https://productimages.withfloats.com/actual/6842b764900dc96c430f8095.png", "tileimageuri": "https://productimages.withfloats.com/tile/6842b764900dc96c430f8095.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-06-06T09:39:25.819Z", "updatedon": "2025-08-28T11:15:31.153Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/trelaqwk-50/2131", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "trelagliptin 50 mg", "category": "DIABETIC RANGE", "tags": [ "Trelagliptin in India", "Trelagliptin brand name", "trelagliptin 50 mg", "trelagliptin 50mg", "trelagliptin 50mg", "trelagliptin 50mg" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "67a35d815432f8f0afe662b4", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "empagliflozin 25mg+ metformin hydrochloride (extended release) 1000 mg", "description": "GLIEMPAFLOZIN MET ER is a combination medication used to manage type 2 diabetes mellitus (T2DM) by helping control blood sugar levels effectively. It contains two powerful anti-diabetic agents, Empagliflozin and Metformin Hydrochloride (Extended Release), which work together to enhance glucose regulation and reduce the risk of diabetes-related complications. This medication is recommended for patients who require additional glycemic control beyond lifestyle changes and monotherapy treatments.\n\n \nKey Benefits\n \n\n Effective Blood Sugar Control – Helps reduce and maintain optimal blood glucose levels in type 2 diabetic patients.\nWeight Management – Empagliflozin promotes caloric loss through urinary glucose excretion, potentially aiding in weight reduction.\nReduced Risk of Cardiovascular Diseases – Beneficial for heart health, lowering the risk of cardiac complications in diabetic patients.\nInsulin Sensitivity Improvement – Metformin enhances insulin function, reducing insulin resistance.\nLower Risk of Hypoglycemia – A balanced mechanism of action ensures stable blood glucose levels without sudden drops.\nKidney Protection – Empagliflozin may help protect against diabetic nephropathy by reducing kidney stress.\nExtended-Release Formula – Ensures long-lasting blood sugar control with a once-daily dosage for improved patient compliance.\n \nHow Does It Work?\n \n\nEmpagliflozin (SGLT2 Inhibitor) – Blocks the SGLT2 protein in the kidneys, preventing glucose reabsorption and promoting its excretion through urine, thereby reducing blood sugar levels.\nMetformin Hydrochloride (Biguanide) – Reduces glucose production in the liver, enhances insulin response, and delays glucose absorption in the digestive tract.\nTogether, they provide a dual action approach for better glycemic control while minimizing side effects like hypoglycemia.\n \nDirections for Use\n \n\nDosage: Take one tablet per day, preferably with food or as directed by your healthcare provider.\nSwallow whole with a glass of water; do not crush or chew.\n Maintain a healthy diet and follow a regular exercise routine for optimal results.\nRegular monitoring of blood sugar levels is advised.\nDo not stop taking this medication without consulting your doctor.\n\n \nSide Effects:\n \n\nSome individuals may experience mild to moderate side effects, including:\n\nFrequent urination (due to glucose excretion)\nDehydration (increased fluid loss)\nNausea, vomiting, or stomach upset\nDiarrhea or constipation\nMetallic taste in the mouth\nLow blood pressure (Hypotension)\nVitamin B12 deficiency (with long-term use of Metformin)\nUrinary tract infections (UTIs) or genital infections\n Seek medical attention if you experience severe allergic reactions, extreme dizziness, or difficulty breathing.", "price": 245.0, "discountamount": 74.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": [ "combination medication", "hypoglycemia directions", "oncedaily dosage", "difficulty breathing", "experience mild", "stop taking", "healthy diet", "chew maintain", "day preferably", "glycemic control", "digestive tract", "sglt2 protein", "diabetic nephropathy", "balanced mechanism", "cardiac complications", "diabetesrelated complications", "constipation metallic taste", "stomach upset diarrhea", "frequent urination due", "moderate side effects", "doctor side effects", "blood sugar levels", "regular exercise routine", "healthcare provider swallow", "minimizing side effects", "dual action approach", "delays glucose absorption", "improved patient compliance", "heart health lowering", "cardiovascular diseases beneficial", "enhance glucose regulation" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2049, "imageuri": "https://productimages.withfloats.com/actual/67a35d9d1b599c6f20ba1fa7.png", "tileimageuri": "https://productimages.withfloats.com/tile/67a35d9d1b599c6f20ba1fa7.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-02-05T12:45:53.712Z", "updatedon": "2025-03-27T09:45:21.627Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/empagliflozin-25mg-metformin-hydrochloride-extended-release-1000-mg/2049", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "GLIEMPAFLOZIN MET ER ", "category": "DIABETIC RANGE", "tags": [ "empagliflozin/metformin 5 mg/1000 mg", "empagliflozin + metformin brand name in india", "empagliflozin + metformin combination brand name", "empagliflozin 12.5 mg+metformin 500 mg price", "Empagliflozin and metformin hydrochloride extended-release tablets", "Empagliflozin and metformin hydrochloride tablets" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "6662b5587de2b5203089e01d", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "VILDIABATE M 850 ", "description": "VILDIABATE M 850 \nMetformin (850mg)SR, Vildagliptin (50mg)\nIntroduction to VILDIABATE M 850\nVILDIABATE M 850 is a combination medication designed to manage type 2 diabetes mellitus effectively. It combines Metformin Hydrochloride Sustained Release (SR) 850mg and Vildagliptin 50mg. This dual-action formulation targets different pathways involved in glucose regulation, providing comprehensive blood sugar control. It is used alongside diet and exercise to improve glycemic control in adults with type 2 diabetes.\n\nKey Components and Their Mechanisms\nMetformin SR 850mg\nMetformin is a biguanide that helps lower blood sugar levels through several mechanisms:\n\nReduces Hepatic Glucose Production: Metformin decreases the amount of glucose produced by the liver.\nImproves Insulin Sensitivity: It enhances the sensitivity of muscle cells to insulin, promoting better glucose uptake and utilization.\nDecreases Intestinal Absorption of Glucose: Metformin reduces the absorption of glucose from the gastrointestinal tract.\nThe sustained-release (SR) formulation ensures a gradual release of the medication, providing prolonged therapeutic effects and reducing the risk of gastrointestinal side effects.\n\nVildagliptin 50mg\nVildagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that works by:\n\nEnhancing Incretin Levels: Vildagliptin inhibits the DPP-4 enzyme, which degrades incretin hormones such as GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic peptide). These hormones increase insulin secretion and decrease glucagon release in a glucose-dependent manner.\nImproving Postprandial Glucose Control: By enhancing the action of incretin hormones, Vildagliptin helps regulate blood sugar levels after meals.\nBenefits of VILDIABATE M 850\nComprehensive Blood Sugar Control\nFasting and Postprandial Glucose Management: The combination of Metformin SR and Vildagliptin effectively manages both fasting and postprandial (after-meal) blood sugar levels.\nImproved Insulin Sensitivity and Secretion: Metformin improves insulin sensitivity, while Vildagliptin enhances insulin secretion in response to meals.\nExtended Release Formulation\nProlonged Effect: The sustained-release formulation of Metformin ensures a steady release of the medication, providing long-lasting blood sugar control and minimizing peaks and troughs in blood sugar levels.\nReduced Gastrointestinal Side Effects: The gradual release of Metformin helps reduce common gastrointestinal side effects associated with immediate-release formulations.\nAdditional Health Benefits\nLow Risk of Hypoglycemia: Vildagliptin has a low risk of causing hypoglycemia (low blood sugar) because it enhances insulin secretion only when blood glucose levels are elevated.\nWeight Neutral: This combination is generally weight-neutral, making it a suitable option for patients concerned about weight gain.\nDosage and Administration\nRecommended Dosage\nDosage: The typical dosage is one tablet taken once or twice daily, preferably with a meal to reduce gastrointestinal side effects.\nAdministration: Swallow the tablet whole with a glass of water. Do not crush, chew, or split the tablet unless advised by your healthcare provider.\nGuidelines for Optimal Use\nConsistent Use: For best results, take VILDIABATE M 850 regularly at the same time each day as prescribed by your healthcare provider.\nMonitor Blood Sugar Levels: Regular monitoring of blood sugar levels is essential to ensure the medication is effectively controlling your diabetes. Adjustments to your treatment plan may be necessary based on these readings.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order Now\nhttps://www.sterisonline.com/product/vildiabate-m-850-133455", "price": 299.0, "discountamount": 89.7, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "GIP", "diet", "Order", "EMAIL", "water", "glass", "liver", "GLP-1", "peaks", "meals", "adults", "amount", "option", "troughs", "Fasting", "exercise", "Low Risk", "patients", "readings", "response", "Enhancing", "same time", "biguanide", "Guidelines", "one tablet", "weight gain", "Optimal Use", "information", "Adjustments", "utilization", "Vildagliptin", "Metformin SR", "sterispharma", "Hypoglycemia", "Introduction", "best results", "sterisonline", "DPP-4 enzyme", "muscle cells", "CALL/WHATSAPP", "treatment plan", "glucose uptake", "steady release", "typical dosage", "Key Components", "Administration", "Weight Neutral", "Consistent Use", "low blood sugar", "Incretin Levels", "gradual release", "glycemic control", "VILDIABATE M 850", "glucagon release", "Prolonged Effect", "DPP-4) inhibitor", "incretin hormones", "insulin secretion", "glucose regulation", "several mechanisms", "different pathways", "Regular monitoring", "healthcare provider", "Insulin Sensitivity", "blood glucose levels", "Intestinal Absorption", "combination medication", "dipeptidyl peptidase-4", "gastrointestinal tract", "dual-action formulation", "meal) blood sugar levels", "type 2 diabetes mellitus", "glucose-dependent manner", "Recommended Dosage Dosage", "Additional Health Benefits", "Hepatic Glucose Production", "Extended Release Formulation", "sustained-release formulation", "prolonged therapeutic effects", "immediate-release formulations", "Postprandial Glucose Management", "long-lasting blood sugar control", "comprehensive blood sugar control", "sustained-release (SR) formulation", "common gastrointestinal side effects", "Reduced Gastrointestinal Side Effects", "Improving Postprandial Glucose Control", "glucose-dependent insulinotropic peptide", "Metformin Hydrochloride Sustained Release" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1504, "imageuri": "https://productimages.withfloats.com/actual/667d44a2576e8da931df856b.png", "tileimageuri": "https://productimages.withfloats.com/tile/667d44a2576e8da931df856b.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-07T07:23:04.367Z", "updatedon": "2024-06-27T10:53:21.595Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/vildiabate-m-850-/1504", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "VILDIABATE M 850 ", "category": "DIABETIC RANGE", "tags": [ "vildagliptin metformin 50/850 price", "vildagliptin and metformin hydrochloride tablets s" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "6662b1e6870e7b20c49e6522", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "VILDIABATE M 500 ", "description": "VILDIABATE M 500 \nMetformin (500mg)SR, Vildagliptin (50mg)\nIntroduction to VILDIABATE M 500\nVILDIABATE M 500 is a combination medication designed to manage type 2 diabetes mellitus effectively. It contains Metformin Hydrochloride Sustained Release (SR) 500mg and Vildagliptin 50mg. This dual-action formula targets different pathways involved in glucose regulation to provide comprehensive blood sugar control. It is used alongside diet and exercise to improve glycemic control in adults with type 2 diabetes.\n\nKey Components and Their Mechanisms\nMetformin SR 500mg\nMetformin is a biguanide that helps lower blood sugar levels through several mechanisms:\n\nReduces Hepatic Glucose Production: Metformin decreases the amount of glucose produced by the liver.\nImproves Insulin Sensitivity: It enhances the sensitivity of muscle cells to insulin, promoting better glucose uptake and utilization.\nDecreases Intestinal Absorption of Glucose: Metformin reduces the absorption of glucose from the gastrointestinal tract.\nThe sustained-release (SR) formulation ensures a gradual release of the medication, providing prolonged therapeutic effects and reducing the risk of gastrointestinal side effects.\n\nVildagliptin 50mg\nVildagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that works by:\n\nEnhancing Incretin Levels: Vildagliptin inhibits the DPP-4 enzyme, which degrades incretin hormones such as GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic peptide). These hormones increase insulin secretion and decrease glucagon release in a glucose-dependent manner.\nImproving Postprandial Glucose Control: By enhancing the action of incretin hormones, Vildagliptin helps regulate blood sugar levels after meals.\nBenefits of VILDIABATE M 500\nComprehensive Blood Sugar Control\nFasting and Postprandial Glucose Management: The combination of Metformin SR and Vildagliptin effectively manages both fasting and postprandial (after-meal) blood sugar levels.\nImproved Insulin Sensitivity and Secretion: Metformin improves insulin sensitivity, while Vildagliptin enhances insulin secretion in response to meals.\nExtended Release Formulation\nProlonged Effect: The sustained-release formulation of Metformin ensures a steady release of the medication, providing long-lasting blood sugar control and minimizing peaks and troughs in blood sugar levels.\nReduced Gastrointestinal Side Effects: The gradual release of Metformin helps reduce common gastrointestinal side effects associated with immediate-release formulations.\nAdditional Health Benefits\nLow Risk of Hypoglycemia: Vildagliptin has a low risk of causing hypoglycemia (low blood sugar) because it enhances insulin secretion only when blood glucose levels are elevated.\nWeight Neutral: This combination is generally weight-neutral, making it a suitable option for patients concerned about weight gain.\nDosage and Administration\nRecommended Dosage\nDosage: The typical dosage is one tablet taken once or twice daily, preferably with a meal to reduce gastrointestinal side effects.\nAdministration: Swallow the tablet whole with a glass of water. Do not crush, chew, or split the tablet unless advised by your healthcare provider.\nGuidelines for Optimal Use\nConsistent Use: For best results, take VILDIABATE M 500 regularly at the same time each day as prescribed by your healthcare provider.\nMonitor Blood Sugar Levels: Regular monitoring of blood sugar levels is essential to ensure the medication is effectively controlling your diabetes. Adjustments to your treatment plan may be necessary based on these readings.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order Now\nhttps://www.sterisonline.com/product/vildiabate-m-500-133454", "price": 289.0, "discountamount": 86.7, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "GIP", "diet", "Order", "EMAIL", "water", "glass", "liver", "GLP-1", "peaks", "meals", "adults", "amount", "option", "troughs", "Fasting", "exercise", "Low Risk", "patients", "readings", "response", "Enhancing", "same time", "biguanide", "Guidelines", "one tablet", "weight gain", "Optimal Use", "information", "Adjustments", "utilization", "Vildagliptin", "Metformin SR", "sterispharma", "Hypoglycemia", "Introduction", "best results", "sterisonline", "DPP-4 enzyme", "muscle cells", "CALL/WHATSAPP", "glucose uptake", "steady release", "typical dosage", "Key Components", "treatment plan", "Weight Neutral", "Consistent Use", "Administration", "Incretin Levels", "gradual release", "low blood sugar", "glycemic control", "DPP-4) inhibitor", "VILDIABATE M 500", "glucagon release", "Prolonged Effect", "incretin hormones", "insulin secretion", "several mechanisms", "different pathways", "Regular monitoring", "glucose regulation", "dual-action formula", "Insulin Sensitivity", "healthcare provider", "blood glucose levels", "Intestinal Absorption", "combination medication", "gastrointestinal tract", "dipeptidyl peptidase-4", "type 2 diabetes mellitus", "glucose-dependent manner", "meal) blood sugar levels", "Recommended Dosage Dosage", "Additional Health Benefits", "Hepatic Glucose Production", "Extended Release Formulation", "sustained-release formulation", "prolonged therapeutic effects", "immediate-release formulations", "Postprandial Glucose Management", "long-lasting blood sugar control", "comprehensive blood sugar control", "sustained-release (SR) formulation", "common gastrointestinal side effects", "Reduced Gastrointestinal Side Effects", "Improving Postprandial Glucose Control", "glucose-dependent insulinotropic peptide", "Metformin Hydrochloride Sustained Release" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1499, "imageuri": "https://productimages.withfloats.com/actual/667d4af8b567218985111efd.png", "tileimageuri": "https://productimages.withfloats.com/tile/667d4af8b567218985111efd.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-07T07:08:22.623Z", "updatedon": "2024-06-27T11:20:23.412Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/vildiabate-m-500-/1499", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "VILDIABATE M 500 ", "category": "DIABETIC RANGE", "tags": [ "vildagliptin metformin 50/1000", "vildagliptin metformin 50/500 price", "ildagliptin and metformin hydrochloride tablets si" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "6662af26db100e1fdc2dcc17", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "VILDIABATE M 1000 ", "description": "VILDIABATE M 1000 \nMetformin (1000mg)SR, Vildagliptin (50mg)\nIntroduction to VILDIABATE M 1000\nVILDIABATE M 1000 is a combination medication designed for the effective management of type 2 diabetes mellitus. It contains Metformin Hydrochloride Sustained Release (SR) 1000mg and Vildagliptin 50mg. This dual-action formula targets different pathways involved in glucose regulation to provide comprehensive blood sugar control. It is used alongside diet and exercise to improve glycemic control in adults with type 2 diabetes.\n\nKey Components and Their Mechanisms\nMetformin SR 1000mg\nMetformin is a biguanide that helps lower blood sugar levels through several mechanisms:\n\nReduces Hepatic Glucose Production: Metformin decreases the amount of glucose produced by the liver.\nImproves Insulin Sensitivity: It enhances the sensitivity of muscle cells to insulin, promoting better glucose uptake and utilization.\nDecreases Intestinal Absorption of Glucose: Metformin reduces the absorption of glucose from the gastrointestinal tract.\nThe sustained release (SR) formulation ensures a gradual release of the medication, providing prolonged therapeutic effects and reducing the risk of gastrointestinal side effects.\n\nVildagliptin 50mg\nVildagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that works by:\n\nEnhancing Incretin Levels: Vildagliptin inhibits the DPP-4 enzyme, which degrades incretin hormones such as GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic peptide). These hormones increase insulin secretion and decrease glucagon release in a glucose-dependent manner.\nImproving Postprandial Glucose Control: By enhancing the action of incretin hormones, Vildagliptin helps regulate blood sugar levels after meals.\nBenefits of VILDIABATE M 1000\nComprehensive Blood Sugar Control\nFasting and Postprandial Glucose Management: The combination of Metformin SR and Vildagliptin effectively manages both fasting and postprandial (after-meal) blood sugar levels.\nImproved Insulin Sensitivity and Secretion: Metformin improves insulin sensitivity, while Vildagliptin enhances insulin secretion in response to meals.\nExtended Release Formulation\nProlonged Effect: The sustained-release formulation of Metformin ensures a steady release of the medication, providing long-lasting blood sugar control and minimizing peaks and troughs in blood sugar levels.\nReduced Gastrointestinal Side Effects: The gradual release of Metformin helps reduce common gastrointestinal side effects associated with immediate-release formulations.\nAdditional Health Benefits\nLow Risk of Hypoglycemia: Vildagliptin, in particular, has a low risk of causing hypoglycemia (low blood sugar) because it enhances insulin secretion only when blood glucose levels are elevated.\nWeight Neutral: This combination is generally weight neutral, making it a suitable option for patients concerned about weight gain.\nDosage and Administration\nRecommended Dosage\nDosage: The typical dosage is one tablet taken once daily, preferably with a meal to reduce gastrointestinal side effects.\nAdministration: Swallow the tablet whole with a glass of water. Do not crush, chew, or split the tablet unless advised by your healthcare provider.\nGuidelines for Optimal Use\nConsistent Use: For best results, take VILDIABATE M 1000 regularly at the same time each day as prescribed by your healthcare provider.\nMonitor Blood Sugar Levels: Regular monitoring of blood sugar levels is essential to ensure the medication is effectively controlling your diabetes. Adjustments to your treatment plan may be necessary based on these readings.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order Now\nhttps://www.sterisonline.com/product/vildiabate-m-1000-133453", "price": 319.0, "discountamount": 95.7, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "GIP", "diet", "GLP-1", "Order", "EMAIL", "water", "glass", "liver", "peaks", "meals", "adults", "amount", "option", "troughs", "Fasting", "exercise", "Low Risk", "patients", "response", "readings", "same time", "Enhancing", "biguanide", "one tablet", "Guidelines", "Optimal Use", "information", "utilization", "weight gain", "Adjustments", "Introduction", "Vildagliptin", "Metformin SR", "VILDIABATE M", "sterispharma", "best results", "Hypoglycemia", "sterisonline", "DPP-4 enzyme", "muscle cells", "CALL/WHATSAPP", "Weight Neutral", "Consistent Use", "Administration", "treatment plan", "steady release", "typical dosage", "Key Components", "glucose uptake", "low blood sugar", "Incretin Levels", "gradual release", "SR) formulation", "glucagon release", "glycemic control", "Prolonged Effect", "DPP-4) inhibitor", "insulin secretion", "incretin hormones", "several mechanisms", "different pathways", "glucose regulation", "Regular monitoring", "dual-action formula", "healthcare provider", "Insulin Sensitivity", "blood glucose levels", "effective management", "Intestinal Absorption", "gastrointestinal tract", "combination medication", "dipeptidyl peptidase-4", "type 2 diabetes mellitus", "glucose-dependent manner", "meal) blood sugar levels", "Recommended Dosage Dosage", "Additional Health Benefits", "Hepatic Glucose Production", "Extended Release Formulation", "sustained-release formulation", "prolonged therapeutic effects", "immediate-release formulations", "Postprandial Glucose Management", "long-lasting blood sugar control", "comprehensive blood sugar control", "common gastrointestinal side effects", "Reduced Gastrointestinal Side Effects", "Improving Postprandial Glucose Control", "glucose-dependent insulinotropic peptide", "Metformin Hydrochloride Sustained Release" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1496, "imageuri": "https://productimages.withfloats.com/actual/6662af29d878d473a9fda03d.png", "tileimageuri": "https://productimages.withfloats.com/tile/6662af29d878d473a9fda03d.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-07T06:56:38.67Z", "updatedon": "2024-06-28T11:39:06.99Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/vildiabate-m-1000-/1496", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "VILDIABATE M 1000 ", "category": "DIABETIC RANGE", "tags": [ "VILDIABATE M 1000", "Metformin (1000mg)SR", "Vildagliptin (50mg)", "Vildagliptin 50mg side effects", "Vildagliptin tablets 50 mg uses", "Vildagliptin 50 mg price", "Vildagliptin 50 mg and metformin 500 mg" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "68e7a474f3481c1f16d3b038", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Sitagliptin (50mg), Metformin Hydrochloride (500mg) & Glimepiride (2mg)", "description": "Sitagliptin 50mg, Metformin Hydrochloride 500mg & Glimepiride 2mg is a combination oral medication designed for the effective management of type 2 diabetes mellitus. This triple-action formula works synergistically to control blood glucose levels by addressing insulin resistance, enhancing insulin secretion, and regulating post-meal sugar spikes. Ideal for patients who require more than one mechanism to maintain stable blood sugar, this combination is often prescribed when monotherapy or dual therapy is insufficient.\n\nUses\n\nManagement of Type 2 Diabetes Mellitus in adults.\n\nHelps in controlling fasting and postprandial blood glucose levels.\n\nRecommended for patients whose blood sugar is not adequately controlled with a single antidiabetic medicine.\n\nCan be used as part of a comprehensive diabetes management plan, including diet and exercise.\n\nKey Benefits\n\nDual Mechanism Control:\n\nMetformin Hydrochloride reduces hepatic glucose production and improves insulin sensitivity.\n\nGlimepiride stimulates pancreatic beta cells to secrete more insulin.\n\nSitagliptin enhances incretin hormones, leading to better regulation of post-meal glucose levels.\n\nEffective Blood Sugar Management:\nHelps maintain optimal fasting and postprandial glucose levels, reducing the risk of diabetes-related complications.\n\nConvenient Combination Therapy:\nCombines three mechanisms in a single tablet, reducing the pill burden and improving patient compliance.\n\nSupports Overall Health:\nHelps prevent long-term complications such as neuropathy, nephropathy, retinopathy, and cardiovascular risks associated with diabetes.\n\nPossible Side Effects\n\nWhile generally well-tolerated, some patients may experience:\n\nGastrointestinal issues: nausea, vomiting, diarrhea, or abdominal discomfort (mainly from Metformin).\n\nHypoglycemia (low blood sugar): more likely due to Glimepiride; symptoms include dizziness, sweating, or shakiness.\n\nAllergic reactions: rash, itching, or swelling in rare cases.\n\nOther mild effects: headache, fatigue, or minor changes in taste.\n\nNote: Patients should always consult their doctor before starting this combination and report any unusual symptoms immediately.\n\nConclusion\n\nThe Sitagliptin, Metformin Hydrochloride & Glimepiride combination provides a powerful, multi-targeted approach to managing type 2 diabetes. By tackling high blood sugar from different angles, it supports better glucose control, enhances overall quality of life, and reduces the risk of diabetes-related complications. When used alongside proper diet, exercise, and medical guidance, this combination can be a cornerstone in effective diabetes management.", "price": 180.0, "discountamount": 54.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2185, "imageuri": "https://productimages.withfloats.com/actual/68e7a47b040520d37b5e6b34.png", "tileimageuri": "https://productimages.withfloats.com/tile/68e7a47b040520d37b5e6b34.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-10-09T12:03:00.012Z", "updatedon": "2025-10-09T12:03:00.012Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/sitagliptin-50mg-metformin-hydrochloride-500mg-glimepiride-2mg-/2185", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "ST GLIPTIN GM", "category": "", "tags": [], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "68b0256b813270ffac595cb0", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "TRELAQWK 100", "description": "TRELAQWK 100 is an advanced oral antidiabetic medication containing Trelagliptin 100 mg, specifically designed for adults with type 2 diabetes mellitus (T2DM). Belonging to the class of Dipeptidyl Peptidase-4 (DPP-4) inhibitors, this formulation helps improve blood glucose control when used along with a proper diet and regular exercise.\nWith its once-weekly dosage regimen, TRELAQWK 100 offers a convenient treatment option, enhancing patient compliance and simplifying long-term diabetes management.\nKey Ingredient\nTrelagliptin 100 mg\nA long-acting DPP-4 inhibitor that regulates blood glucose levels by enhancing incretin hormones. These incretins stimulate insulin secretion and suppress glucagon release, helping to achieve better glycemic control.\nKey Benefits of TRELAQWK 100\nWeekly dosing ensures greater convenience and adherence\nReduces both fasting and postprandial blood sugar levels\nSupports natural blood sugar regulation without weight gain\nLow risk of hypoglycemia, especially when used as monotherapy or with non-insulin therapies\nCan be prescribed as monotherapy or in combination with other antidiabetic agents like metformin or sulfonylureas\nHow TRELAQWK 100 Works\nTRELAQWK 100 functions by blocking the DPP-4 enzyme, which normally degrades incretin hormones such as GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide).\nThese incretin hormones:\nStimulate insulin secretion in response to meals\nReduce glucagon release, lowering blood sugar levels\nThanks to its extended half-life, trelagliptin allows for once-weekly dosing, unlike other DPP-4 inhibitors that require daily administration.\nDirections for Use\nDosage: Take one tablet of TRELAQWK 100 once weekly, or as directed by your physician\nAdministration: May be taken with or without food, ideally on the same day each week\nMissed dose: Do not double the dose; consult your healthcare provider for guidance\nPossible Side Effects\nTRELAQWK 100 is usually well-tolerated, but some individuals may experience:\nMild headache\nNasopharyngitis (common cold-like symptoms)\nConstipation\nUpper respiratory tract infections\nRare skin allergies (rash, itching)\n👉 If you experience persistent abdominal pain, severe rashes, or symptoms suggestive of pancreatitis, stop the medication and seek medical care immediately.", "price": 550.0, "discountamount": 165.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2166, "imageuri": "https://productimages.withfloats.com/actual/68b0256ebb42c3d551ad314c.png", "tileimageuri": "https://productimages.withfloats.com/tile/68b0256ebb42c3d551ad314c.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-08-28T09:46:19.602Z", "updatedon": "2025-08-28T09:46:19.602Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/trelaqwk-100/2166", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "trelagliptin 100 mg", "category": "DIABETIC RANGE", "tags": [], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "68b02393f5434d48fca8b8ca", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "TRELAQWK 50", "description": "TRELAQWK 50 is a modern oral antidiabetic tablet containing Trelagliptin 50 mg, specially developed for adults with type 2 diabetes mellitus. This once-weekly medication helps regulate blood sugar effectively, offering both convenience and strong clinical outcomes. With its advanced formulation, TRELAQWK 50 supports better glycemic control, making it easier for patients to lead a balanced and healthier lifestyle.\nManufactured under strict quality standards, TRELAQWK 50 ensures patient compliance, long-term safety, and efficacy in diabetes management.\nKey Ingredient\nTrelagliptin (50 mg):\nA unique, long-acting DPP-4 (dipeptidyl peptidase-4) inhibitor that allows weekly dosing, ensuring higher treatment adherence while maintaining effective control over blood glucose levels.\nKey Benefits of TRELAQWK 50\nProvides consistent blood sugar management with just one tablet per week\nEnhances insulin secretion while lowering glucagon levels in a glucose-dependent manner\nHelps reduce both fasting and postprandial blood glucose\nConvenient choice for patients with busy schedules who struggle with daily tablets\nLow risk of hypoglycemia when used as monotherapy\nSupports long-term improvement in HbA1c levels\nMechanism of Action – How TRELAQWK 50 Works\nTRELAQWK 50 works by blocking the DPP-4 enzyme, which normally degrades incretin hormones such as GLP-1 and GIP. These incretins are vital for maintaining blood sugar balance. By prolonging incretin activity, trelagliptin:\nStimulates insulin secretion from the pancreas\nReduces glucagon release from alpha cells\nHelps lower blood sugar, particularly after meals\nThis mechanism provides both effective glycemic control and improved patient compliance.\nDirections for Use\nTake one tablet of TRELAQWK 50 once a week, on the same day each week\nCan be taken with or without food\nSwallow whole with a glass of water\nFollow your doctor’s advice for dosage adjustment\nDo not double the dose if missed; consult your healthcare provider\nPossible Side Effects\nTRELAQWK 50 is usually well-tolerated. However, some patients may experience:\nMild headache\nNasopharyngitis (cold-like symptoms)\nDiarrhea\nStomach discomfort or indigestion\nRare allergic reactions (rash, itching)\nIf any unusual or persistent side effects occur, seek medical advice promptly.", "price": 375.0, "discountamount": 112.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2165, "imageuri": "https://productimages.withfloats.com/actual/68b023971624ba892ffd8c69.png", "tileimageuri": "https://productimages.withfloats.com/tile/68b023971624ba892ffd8c69.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-08-28T09:38:27.036Z", "updatedon": "2025-08-28T09:38:27.036Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/trelaqwk-50/2165", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "trelagliptin 50 mg", "category": "DIABETIC RANGE", "tags": [], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false } ], "hasmoreitems": false, "isapirequest": false, "totalresults": 27, "query": null, "floatingpoint": null }